ArticleThe Journal of clinical investigation1997
Lupus-specific antibodies reveal an altered pattern of somatic mutation.
Article in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 52 citations in OpenAlex.
- Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.Arthritis research & therapy · 2006Trial
- Mucosal immunology of HIV infection.Immunological reviews · 2013Review
- Role of Structure-Based Changes due to Somatic Mutation in Highly Homologous DNA-Binding and DNA-Hydrolyzing Autoantibodies Exemplified by A23P Substitution in the VH Domain.Autoimmune diseases · 2012Article
- Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.Arthritis and rheumatism · 2011Article
- Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage.Autoimmunity reviews · 2007Review
- Defective B cell tolerance checkpoints in systemic lupus erythematosus.The Journal of experimental medicine · 2005Article
- Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies.The Journal of experimental medicine · 2004Article
- A genetic lesion that arrests plasma cell homing to the bone marrow.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.Immunological reviews · 2003Review
- Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus.Annals of the rheumatic diseases · 2003Article
- Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus.The Journal of experimental medicine · 2002Article
- Somatic hypermutation in human B cell subsets.Springer seminars in immunopathology · 2001Review
- Perturbations in the impact of mutational activity on Vlambda genes in systemic lupus erythematosus.Arthritis research · 2001Article
- Immunoglobulin heavy chain variable region gene replacement As a mechanism for receptor revision in rheumatoid arthritis synovial tissue B lymphocytes.The Journal of experimental medicine · 2000Article
- Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus.The Journal of clinical investigation · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The F4 idiotype is a heavy chain determinant expressed almost exclusively on IgG immunoglobulins and is highly associated with specificity for double-stranded DNA. Since high-titered F4 expression is present predominantly in sera of patients with systemic lupus erythematosus (SLE), we thought F4+ IgG antibodies might constitute a useful subset of immunoglobulins in which to investigate lupus-specific alterations in variable (V) region gene expression or in the process of somatic mutation. This molecular analysis of F4+ B cell lines generated from lupus patients demonstrates that despite the strong association of F4 reactivity with specificity for native DNA, there is no apparent VH gene restriction. Furthermore, VH gene segments encoding these antibodies are also used in protective immune responses. An examination of the process of somatic mutation in F4+ antibodies showed no abnormality in frequency of somatic mutation nor in the distribution of mutations in complementarity-determining regions or framework regions. However, there was a decrease in targeting of mutations to putative mutational hot spots. This subtle difference in mutations present in these antibodies may reflect an intrinsic defect in mutational machinery or, more likely, altered state of B cell activation that affects the mutational process and perhaps also negative selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.